Buyer guide
Outsourced omics data often lacks the methodological metadata needed to reproduce or publish the analysis—and providers who refuse protocol or software-version details are an explicit warning sign (Sloan & Stenglein, 2025). After reading this page, you will recognize nine practical red flags, know when to probe versus walk away, and have a due-diligence script to use before sharing raw data.
| Fact | Detail | Source |
|---|---|---|
| Outsourced data documentation gap | Centralized or outsourced data generation frequently lacks methodological metadata; refusal to provide protocol details is a red flag | (Sloan & Stenglein, 2025) |
| NGS methods reporting | Fewer than half of 50 surveyed NGS papers provided software-version or parameter details | (Piccolo & Frampton, 2016) |
| Notebook reproducibility | 5.6% of biomedical Jupyter notebooks with declared dependencies produced identical results on re-execution (879 of 15,817) | (Samuel & Mietchen, 2024) |
| Bioinformatics reproduction attempts | NIH intramural workshops (2018–2019) could not reproduce any of five bioinformatics studies, citing missing data, software, and documentation | (Ziemann et al., 2023) |
| Researcher reproducibility experience | >70% of 1,576 surveyed researchers failed to reproduce another scientist's experiment | (Baker, 2016) |
| Funder data-sharing requirement | NIH Data Management and Sharing Policy effective 25 January 2023; scientific data needed to validate and replicate findings must be shared | (NIH, 2023) |
| Funder software expectation | Wellcome requires original software needed to replicate analyses to be available at publication | (Wellcome Trust, n.d.) |
A bioinformatics CRO contract determines whether you can answer reviewer questions, comply with funder data-management plans, and rerun analyses after staff turnover. Red flags ignored at selection become expensive problems at peer review.
Ioannidis et al. (2009) found data unavailability and incomplete documentation—not biology—blocked reproduction of published microarray results; only 2 of 18 studies could be reproduced in principle and 10 could not be reproduced at all. Ziemann et al. (2023) reported NIH intramural workshops (2018–2019) could not reproduce any of five bioinformatics studies, citing missing data, software, and documentation. Spotting warning signs before you transfer FASTQ files is cheaper than discovering them after a grant year is spent.
These warning signs appear in reproducibility studies and failed outsourcing engagements. None alone may be disqualifying, but patterns matter—especially combinations of reproducibility and IP red flags.
PDF reports or gene lists without scripts, parameter logs, or a runnable environment cannot be verified. Sandve et al. (2013) emphasize archiving software versions and parameters; Wellcome Trust (n.d.) expects replication software at publication. Probe: "Can you deliver a version-locked environment that reproduces every figure?"
Outsourced data often lacks protocol and software-version details unless the client asks proactively (Sloan & Stenglein, 2025); refusal is a red flag. Probe: "Will chemistry, instrument model, and software versions ship automatically with every deliverable?"
Without a conda environment.yml or Python requirements.txt, your lab cannot reliably rerun the analysis. Recreating NGS workflows without version metadata can require hundreds of hours (Piccolo & Frampton, 2016). Probe: "Will you provide an environment.yml or requirements.txt that reproduces all outputs?"
Flat per-sample quotes without milestone deliverables or acceptance criteria invite scope disputes. Low headline prices may exclude figures or reviewer support. Probe: "List exact files at each milestone, with acceptance criteria."
Platform licenses are not scientist-led analysis. A UI without a named analyst who understands QC and batch effects is a tool subscription. Probe: "Who interprets QC failures—a named scientist or an account manager?"
Requesting raw FASTQ or BAM before NDA, or inability to describe encrypted transfer (SFTP, S3 with SSE-KMS), isolated compute, and certified deletion, signals unreadiness. Probe: "Will you sign our NDA before upload, and where will files be stored?"
"Guaranteed differential expression" or manuscript-ready output in days for a large cohort signals sales pressure; rush schedules often skip QA. Probe: "What is typical queue time plus QA depth for our sample size—not your fastest case?"
Ambiguous ownership of custom scripts and outputs causes publication problems. Red flags: exclusive pipeline rights, no Git handoff, or blocked export. Probe: "Who owns custom code and processed outputs?"
Sales-led discovery with no named scientist, or dismissing reproducibility as "technical details," leaves no accountability when QC fails. Probe: "Who owns QC decisions, and how often will we meet during analysis?"
| Red flag | First response | Walk away if |
|---|---|---|
| Black-box deliverables | Require reproducibility package in SOW; paid pilot on subset | Refuses code, environment files, or parameter logs after written request |
| Metadata only on request | Contractually require automatic metadata with data | Refuses protocol or version details (Sloan & Stenglein, 2025) |
| No version-pinned environment | Request sample environment.yml or requirements.txt before full project | Cannot deliver a documented reproducibility package |
| Vague SOW | Send written deliverable list; compare vendors | Will not itemize milestones or acceptance criteria |
| Software sold as analysis | Confirm scientist-led interpretation in contract | No named analyst assigned |
| No NDA before transfer | Pause sharing until NDA and security questionnaire complete | Refuses NDA or cannot describe encryption and isolation |
| Guaranteed results / rush timeline | Request realistic timeline with QC milestones | Dismisses QC or promises outcomes regardless of data quality |
| Unclear IP | Negotiate client ownership before signing | Retains exclusive rights or blocks data export |
| Sales-led scoping | Require scientist on next call | No scientist or reproducibility questions brushed off |
Researchers spot warning signs but override them for speed or cost: lowest bid without SOW comparison; sequencing bundles treated as manuscript-ready without parameter docs (Piccolo & Frampton, 2016); deferred IP; assuming reproducibility is the CRO's problem when funders hold the grantee responsible (NIH, 2023; Sloan & Stenglein, 2025); or accepting black-box output when documentation gaps—not bad science—blocked Ziemann et al.'s (2023) cited workshop cases.
Run this script on every finalist. See the bioinformatics CRO selection guide for a fifteen-question RFP.
Score the shortlist against all nine red flags; eliminate providers with multiple walk-away signals.
Send written questions on deliverables, reproducibility package, IP, and security; compare answers.
Sign a project NDA and complete a security questionnaire before any upload.
Require milestone-based pricing with acceptance criteria—not open-ended hourly billing without caps.
Run a paid pilot on a subset: QC report plus one figure with scripts, environment file, and parameter logs.
Confirm funder compliance—deliverables must support your data management plan (NIH, 2023; Wellcome Trust, n.d.).
Negotiate IP in writing—client ownership of custom code and processed outputs before signing.
The highest-stakes warnings are black-box deliverables, refusal to provide methodological metadata, unclear IP, and data transfer before NDA. Combined reproducibility and IP red flags warrant extra scrutiny—not automatic rejection, but a reason to pause. Secondary flags—vague SOWs and sales-led scoping—may be negotiable via a paid pilot with reproducibility artifacts and a named scientist.
Only for exploratory internal review—not grant-funded or peer-reviewed work. For those projects, a PDF alone conflicts with reproducibility expectations (Sandve et al., 2013; NIH, 2023). Treat report-only tiers as separate products, not substitutes for a Methods section you can defend to reviewers or document in your approved data management plan.
For publication-bound work, yes—unless they provide an equivalent reproducibility package (version-pinned environment file, documented scripts, parameter logs, figure regeneration instructions). Proprietary tools may not ship source code; require documented versions and inputs sufficient for verification. Refusal to share anything runnable after a written request is a walk-away signal. Test with a paid pilot before committing.
A software company sells platform access or licenses; a CRO sells scientist-led analysis under a defined SOW. Ask who interprets results, who handles QC failures, and whether deliverables include custom interpretation—not dashboard exports. If no named analyst is assigned and pricing is SaaS-based, you are buying a tool. Check for milestone deliverables and acceptance criteria, not seat count.
Not always for QC, but often for manuscripts. Many bundled pipelines have limited parameter documentation (Piccolo & Frampton, 2016; Sloan & Stenglein, 2025). For peer-reviewed work, verify version-pinned scripts with documentation, custom statistics, figure source files, and reviewer support—or budget for a specialist CRO for the analysis layer. Low per-sample price alone is not a red flag; missing documentation is.
Walk away from providers who request data before NDA, cannot specify encrypted transfer (SFTP, S3 with SSE-KMS, or equivalent), lack isolated per-client compute, or have no written retention and deletion policy. For human-subject data, confirm a HIPAA business associate agreement or GDPR processor agreement where applicable. Ask where files are stored, who can access them, and how deletion is certified.
Rarely without full re-analysis. Missing version metadata and parameter logs often make reconstruction impossible or cost hundreds of hours (Piccolo & Frampton, 2016). Reviewer requests for code are common; fixing gaps after delivery costs more than specifying reproducibility deliverables upfront. Specify scripts, environment files, and parameter logs as acceptance criteria upfront.
Yes. The grantee remains responsible. NIH's Data Management and Sharing Policy (effective January 2023) requires sharing scientific data needed to validate and replicate findings; subcontracted analysis must produce artifacts compatible with your approved plan (NIH, 2023). A CRO that cannot deliver metadata, documented scripts, and version-pinned environment files puts your grant at risk.
Yes. Logos reflect past projects, not your SOW. Ask whether those papers included code delivery, who owned analysis artifacts, and whether the same team will run your project. A strong publication list does not replace a paid pilot and written reproducibility questions before you sign a contract.
Tell us:
We'll tell you:
Contact us to start with a free consultation. Need everyday bench calculators? Try our free lab tools.
